CatalYm Appoints Scott Clarke as CEO Ahead of Global Clinical Expansion
Portfolio - People | Jan 09, 2025 | Bioqube Ventures NV
CatalYm has announced the appointment of Scott Clarke as its new Chief Executive Officer. Clarke brings over twenty years of experience in the biopharmaceutical sector, having led previous companies through significant transactions and product development milestones. His arrival coincides with CatalYm's initiation of a global Phase 2b clinical development program for its lead therapeutic candidate, visugromab, which is aimed at treating non-squamous non-small-cell lung cancer and other tumor types. The company recently closed an oversubscribed $150 million Series D financing round and has published data supporting visugromab's effectiveness. CatalYm is positioning itself robustly in the biopharmaceutical space with strong backing from investors such as Bioqube Ventures and others.
Sectors
- Biopharmaceutical
- Private Equity
Geography
- United States – Scott Clarke, the new CEO, will be based in the US to oversee CatalYm's operations, marking significant expansion efforts in this region.
- Germany – CatalYm is based in Munich, Germany, anchoring its operations in a key European biopharmaceutical hub.
Industry
- Biopharmaceutical – The article discusses CatalYm's development of visugromab, a novel cancer treatment, highlighting its expansion into broader clinical trials.
- Private Equity – Bioqube Ventures, a private equity firm, is noted as one of the backers of CatalYm, showcasing its role in financing innovative biopharmaceutical ventures.
Financials
- $150 million – Amount raised by CatalYm in its Series D financing, indicating strong investor confidence.
- $85 million – Amount raised by Scott Clarke during his tenure at Ambagon Therapeutics, showcasing his financial management experience.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| CatalYm | Target Company | Company | A biopharmaceutical company developing novel cancer treatments, notably visugromab. |
| Scott Clarke | Chief Executive Officer | People | The newly appointed CEO of CatalYm with extensive experience in biopharmaceutical leadership. |
| Bioqube Ventures NV | Investor | Company | A private equity firm investing in CatalYm's growth and development initiatives. |
| Jon Edwards | Interim Chair of the Board of Directors | People | Interim Chair at CatalYm, advocating the strategic appointment of Scott Clarke. |